drugset / Trial / NCT01909557

Acetyl-L-Carnitine Supplementation During HCV Therapy With Peg IFN-α2b Plus Ribavirin: Effect on Work Performance.

NCT01909557

Phase 3 Completed 62 enrolled University of Catania
RandomizedParallel-groupDouble-blindTreatment

Summary

To assess the effects of Acetyl-L-Carnitine, probiotics and antioxidant nutritional substances administration on work productivity, daily activity, and fatigue in subjects with chronic hepatitis C treated with Pegylated-Interferon-α2b and Ribavirin.

Timeline

Start
2010-01
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acetylcarnitine Small molecule 2 g

Indications

No indication recorded.